keyword
https://read.qxmd.com/read/38529183/unlocking-the-potential-of-fondaparinux-guideline-for-optimal-usage-and-clinical-suggestions-2023
#1
REVIEW
Qinan Yin, Lizhu Han, Yin Wang, Fengjiao Kang, Fengqun Cai, Liuyun Wu, Xingyue Zheng, Lian Li, Li E Dong, Limei Dong, Shuhong Liang, Min Chen, Yong Yang, Yuan Bian
Background: Thromboembolic disease is associated with a high rate of disability or death and gravely jeopardizes people's health and places considerable financial pressure on society. The primary treatment for thromboembolic illness is anticoagulant medication. Fondaparinux, a parenteral anticoagulant medicine, is still used but is confusing due to its disparate domestic and international indications and lack of knowledge about its usage. Its off-label drug usage in therapeutic settings and irrational drug use are also common...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38487678/fibrinolysis-biomarker-thrombin-and-activated-protein-c-level-alterations-after-coagulation-activation-depend-on-type-of-thrombophilia-and-clinical-phenotype
#2
JOURNAL ARTICLE
Sara Reda, Nadine Schwarz, Jens Müller, Hannah L McRae, Johannes Oldenburg, Bernd Pötzsch, Heiko Rühl
BACKGROUND: Recently, we have shown alterations in the anticoagulant response to recombinant activated factor VII (rFVIIa)-induced coagulation activation in patients with thrombophilia. OBJECTIVES: This study aimed to extend this in vivo model to fibrinolysis biomarkers. METHODS: This interventional in vivo study included 56 patients with thrombophilia and previous venous thromboembolism (VTE+), 38 without VTE (VTE-), and 35 healthy controls...
February 2024: Research and Practice in Thrombosis and Haemostasis
https://read.qxmd.com/read/38445123/perioperative-management-of-a-frail-patient-with-bernard-soulier-syndrome
#3
Pedro Goncalves, Magna Fortunato
Bernard-Soulier syndrome (BSS) is an autosomal recessive inherited bleeding disorder characterized by prolonged bleeding time, thrombocytopenia, and giant platelets. Patients with BSS are at an increased risk of bleeding, especially during traumatic injury and surgical procedures. The literature on the anesthetic management of patients with BSS is limited. In this report, we detail the successful management of a frail patient with BSS who underwent a major surgical procedure. Despite comprehensive clinical monitoring and an extended pharmacological strategy, a hemorrhagic complication occurred in the later postoperative phase, emphasizing the necessity for continued support and vigilant clinical monitoring due to the ongoing bleeding risk associated with these patients...
February 2024: Curēus
https://read.qxmd.com/read/38439143/immune-gene-polymorphisms-associated-with-poor-response-to-platelet-transfusion-and-recombinant-factor-vii-administration-in-glanzmann-thrombasthenia
#4
JOURNAL ARTICLE
Majid Naderi, Ilia Mirzaei, Omid Seidizadeh, Abolfazl Parsi Moud, Hosna Sarani, Amir Avan, Mohsen Taheri, Danial Jahantigh, Mohammad Reza Keramati, Tayebeh Sohrabi
INTRODUCTION: Poor response to platelet and recombinant factor VII administration is a major problem in patients with Glanzmann Thrombasthenia (GT). The risk factors associated with poor response to treatment in these patients are unknown. Some genetic variations of cytokines may contribute to therapy resistance. AIMS: We evaluated, for the first time, whether genetic polymorphisms on cytokine genes are related to poor treatment response in GT patients. METHODS: We enrolled 30 patients with GT (15 resistant and 15 non-resistant) and 100 healthy controls...
March 4, 2024: Haemophilia: the Official Journal of the World Federation of Hemophilia
https://read.qxmd.com/read/38318153/site-directed-mutagenesis-of-tissue-factor-pathway-inhibitor-binding-exosite-d60a-on-factor-vii-results-in-a-new-factor-vii-variant-with-lower-coagulant-activity
#5
JOURNAL ARTICLE
Karnsasin Seanoon, Vorawat Kitiyanant, Panwajee Payongsri, Nongnuch Sirachainan, Pantep Angchaisuksiri, Ampaiwan Chuansumrit, Suradej Hongeng, Pansakorn Tanratana
BACKGROUND: Recombinant factor (F)VIIa (rFVIIa) has been approved by the US Food and Drug Administration for the treatment of hemophilia A and B with inhibitors and congenital FVII deficiency. Moreover, the investigational uses of rFVIIa are becoming of interest since it can be used to treat various clinical bleeding conditions. However, there is evidence showing that rFVIIa is a potent procoagulant agent that potentially leads to an increased risk of thrombotic complications. OBJECTIVES: To design a new rFVII with lower coagulant activity that could potentially be used as an alternative hemostatic agent aiming to minimize the risk of thrombogenicity...
January 2024: Research and Practice in Thrombosis and Haemostasis
https://read.qxmd.com/read/38291654/safety-of-recombinant-activated-factor-vii-for-treatment-of-breakthrough-bleeds-in-patients-with-congenital-haemophilia-a-and-inhibitors-receiving-emicizumab-prophylaxis-review-of-the-real-world-evidence
#6
REVIEW
Gili Kenet, Teruhisa Fujii
BACKGROUND: Emicizumab is used as a subcutaneous prophylaxis for prevention of bleeding episodes in patients with haemophilia A (HA) with and without inhibitors. While low bleeding rates were observed in clinical trials, patients still experience breakthrough bleeds (BTBs) with emicizumab in the real-world. Current guidelines recommend use of recombinant activated factor VII (rFVIIa) for treatment of BTBs in patients with inhibitors. Due to thrombotic events observed in the HAVEN 1 study, activated prothrombin complex concentrate (aPCC) should be used with caution...
January 30, 2024: Haemophilia: the Official Journal of the World Federation of Hemophilia
https://read.qxmd.com/read/38289523/comparison-of-hvt-nd-recombinant-and-convection-based-newcastle-disease-vaccination-programs-in-the-protection-against-the-genotype-vii-ndv-challenges-an-experimental-study
#7
JOURNAL ARTICLE
Mohammad Kazem Rajab, Mohmmad Hassan Bozorgmehri Fard, Arash Ghalyanchilangeroudi, Hossein Hosseini, Saeed Charkhkar
Newcastle disease virus (NDV) belongs to the Avulavirus genus and Paramyxoviridae family virus that causes acute, highly infectious Newcastle disease in poultry. The two proteins of haemagglutinin neuraminidase (HN) and fusion (F) are key virulence factors with an important role in its immunogenicity. Genotype VII NDV is still among the most serious viral hazards to the poultry industry worldwide. In this study, a commercial vector vaccine (HVT-NDV) was evaluated compared to the conventional vaccination strategy against Iranian genotype VII...
January 30, 2024: Virus Genes
https://read.qxmd.com/read/38282333/patient-blood-management-guideline-for-adults-with-critical-bleeding
#8
JOURNAL ARTICLE
Biswadev Mitra, Margaret Jorgensen, Michael C Reade, Anastazia Keegan, Anthony Holley, Shannon Farmer, Nichole Harvey, James Winearls, Michael Parr, Craig J French
INTRODUCTION: The management of patients with critical bleeding requires a multidisciplinary approach to achieve haemostasis, optimise physiology, and guide blood component use. The 2011 Patient blood management guidelines: module 1 - critical bleeding/massive transfusion were updated and published. Systematic reviews were conducted for pre-specified research questions, and recommendations were based on meta-analyses of included studies. MAIN RECOMMENDATIONS: The critical bleeding/massive transfusion guideline includes seven recommendations and 11 good practice statements addressing: major haemorrhage protocols (MHPs) facilitating a multidisciplinary approach to haemorrhage control, correction of coagulopathy and normalisation of physiological derangement; measurement of physiological, biochemical and metabolic parameters in critical bleeding/massive transfusion; the optimal ratio of red blood cells to other blood components; the use of tranexamic acid; viscoelastic haemostatic assays; and cell salvage...
January 28, 2024: Medical Journal of Australia
https://read.qxmd.com/read/38248356/hematological-complications-in-a-covid-19-patient-a-case-report
#9
Eleonora Ianuà, Mario Caldarelli, Giuseppe De Matteis, Rossella Cianci, Giovanni Gambassi
Hemophilia A is a hemorrhagic disorder caused by insufficient or inadequate coagulation factor VIII activity. Two different forms are described: congenital, hereditary X-linked, and acquired. Acquired hemophilia A (AHA) is a rare condition and it is defined by the production of autoantibodies neutralizing factor VIII, known as inhibitors. We report the case of a 72-year-old man with a clinical diagnosis of AHA after SARS-CoV-2 infection, which has been described in association with several hematological complications...
December 24, 2023: Diseases (Basel)
https://read.qxmd.com/read/38244305/advances-and-challenges-in-the-purification-of-recombinant-coagulation-factors-a-review
#10
REVIEW
Linling Yu, Dongmei Yang, Mengyao Chu, Yan Sun
Hemostasis is a complex process for the cessation of bleeding from an injured blood vessel, involving the interplay of 12 coagulation factors in the coagulation cascade with activated blood platelets and the vessel wall. Hence, the coagulation factors are important to control hemorrhage. However, the low abundance of many coagulation factors in human plasma proteins limited their production in therapeutic drugs and their clinical applications. With the development of modern biotechnology, commercially manufactured recombinant coagulation factors became available as hemostatic therapeutics, emerging a huge potential in pharmaceutical manufacturing market...
January 16, 2024: Journal of Chromatography. A
https://read.qxmd.com/read/38224132/extracellular-vesicle-tissue-factor-activity-assay
#11
JOURNAL ARTICLE
Yohei Hisada, Nigel Mackman
Tissue factor (TF) is a transmembrane receptor for factor (F) VII and FVIIa. The TF/FVIIa complex initiates the coagulation cascade by activating both FIX and FX. TF is released from cells into the circulation in the form of extracellular vesicles (EVs). The level of TF-positive (+ ) EVs is increased in various diseases, including cancer, bacterial and viral infections, and cirrhosis, and is associated with thrombosis, disseminated intravascular coagulation, disease severity, and mortality. There are two ways to measure TF+ EVs in plasma: antigen- and activity-based assays...
December 29, 2023: Journal of Visualized Experiments: JoVE
https://read.qxmd.com/read/38220518/trends-in-the-use-of-recombinant-activated-factor-vii-and-prothrombin-complex-concentrate-in-heart-transplant-patients-in-virginia
#12
JOURNAL ARTICLE
Michael Mazzeffi, Jared Beller, Raymond Strobel, Anthony Norman, Alexander Wisniewski, Judy Smith, Clifford E Fonner, John McNeil, Alan Speir, Ramesh Singh, Daniel Tang, Mohammed Quader, Leora Yarboro, Nicholas Teman
OBJECTIVES: To explore trends in intraoperative procoagulant factor concentrate use in patients undergoing heart transplantation (HTx) in Virginia. Secondarily, to evaluate their association with postoperative thrombosis. DESIGN: Patients who underwent HTx were identified using a statewide database. Trends in off-label recombinant activated factor VII (rFVIIa) use and on-label and off-label prothrombin complex concentrate (PCC) use were tested using the Mantel-Haenszel test...
October 4, 2023: Journal of Cardiothoracic and Vascular Anesthesia
https://read.qxmd.com/read/38214949/determinants-of-bleeding-before-and-during-immune-tolerance-in-222-boys-with-severe-hemophilia-a-and-inhibitors-5-bu
#13
JOURNAL ARTICLE
Kathelijn Fischer, Gili Kenet, Karin Kurnik, Manuel Carcao, Johannes Oldenburg, Torben Stamm-Mikkelsen, Ana Rosa Cid Haro, Minna Koskenvuo, Jan Blatny, Christoph Königs
Prevention of bleeding and its consequences is the main goal of hemophilia treatment and determines treatment choices for patients who develop inhibitors. To assess bleeding before and during immune tolerance induction (ITI) and its association with ITI regimen and inhibitor titer, we selected and analyzed data on patients receiving high-titer inhibitors from the international prospective PedNet cohort study. In total, 222 patients with severe hemophilia A and inhibitor titers of >5 Bethesda units (BU) were followed from the first positive to the first negative inhibitor result (median overall follow-up, 1...
January 23, 2024: Blood Advances
https://read.qxmd.com/read/38206721/acquired-isolated-factor-vii-deficiency-in-a-patient-with-myxoid-pleomorphic-liposarcoma-case-report
#14
JOURNAL ARTICLE
Mansour Aljabry, Manar Aleid, Shahad Almutairi, Reema AlSerhani, Shahad Alsahil, Ghazi Alotaibi
INTRODUCTION: Acquired factor VII (FVII) deficiency is a rare condition with various causes, including acquired inhibitors to FVII, liver disease, and malignancies. Myxoid pleomorphic liposarcoma is a rare and aggressive form of soft tissue sarcoma that can cause a range of clinical manifestations, including bleeding and clotting disorders. PATIENT CONCERNS AND DIAGNOSIS: We present a case report of a 21-year-old man with severe acquired FVII deficiency due to mediastinal myxoid pleomorphic liposarcoma...
December 29, 2023: Medicine (Baltimore)
https://read.qxmd.com/read/38206717/patient-with-congenital-factor-vii-deficiency-undergoing-brain-tumor-neurosurgery-successfully-treated-with-recombinant-factor-viia-and-fresh-frozen-plasma-a-case-report-and-literature-review
#15
JOURNAL ARTICLE
Chaoyu Huang, Yongjia Yu, Ningneng Zhai, Wuning Mo, Faquan Lin
RATIONALE: Congenital factor VII deficiency is the most common among rare bleeding disorders, characterized by spontaneous or traumatic bleeding. The clinical manifestation is heterogeneous, ranging from asymptomatic phenotype to life-threatening hemorrhages. Intracranial hemorrhage is a common complication of brain tumor neurosurgery, which significantly challenges the perioperative management of patients with hemostatic defects. PATIENT CONCERNS: This report presented a 55-year-old man with congenital factor VII deficiency, who had no history of hemorrhage or family history...
December 29, 2023: Medicine (Baltimore)
https://read.qxmd.com/read/38181709/detection-and-quantification-of-single-chain-rfvii-impurity-in-final-drug-products-by-se-uplc-and-ce-sds-as-an-alternative-to-sds-page
#16
JOURNAL ARTICLE
Mohsen Kahrizi, Behnaz Molavi, Mahshid Mirshahi, Mohsen Yazdani, Allahyar Tayebian, Hossein Behrooz
Recombinant factor VII, produced in recombinant BHK cell line, is secreted as a single chain zymogen form (rFVII, non-activated) in cell culture supernatant and subsequently converts to its active form during anion exchange chromatography step in the downstream purification process, with the aid of calcium ion. Single chain rFVII impurity (non-activated form) in final drug products should not exceed more than 3.0 % of total rFVIIa content. Therefore, one of the most essential quality control tests in pharmaceutical companies is to precisely quantify and report this impurity...
December 30, 2023: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://read.qxmd.com/read/38179703/double-jeopardy-glomangiopericytoma-and-glanzmann-thrombasthenia-resulting-in-recurrent-epistaxis-a-case-report
#17
JOURNAL ARTICLE
Emna Hammami, Léa Fath, Christian Debry, Dominique Desprez
Glanzmann thrombasthenia is a rare bleeding disorder induced by inherited defects of the platelet membrane αIIbβ3 glycoprotein. Glomangiopericytoma, on the other hand, is a very rare sinonasal tumor demonstrating a perivascular myoid phenotype. We herein report the first described case in the literature of Glanzmann thrombasthenia and glomangiopericytoma. The patient is a 40-year-old man diagnosed with type 1 Glanzmann thrombasthenia who presented with repetitive and profuse posterior epistaxis initially managed with platelet transfusions and recombinant activated factor VII (rFVIIa)...
December 21, 2023: Blood Coagulation & Fibrinolysis: An International Journal in Haemostasis and Thrombosis
https://read.qxmd.com/read/38129208/retrospective-comparison-of-recombinant-activated-factor-vii-versus-4-factor-prothrombin-complex-concentrate-in-cardiac-surgical-patients
#18
JOURNAL ARTICLE
David Faraoni, Anna Guindi, Ashish A Ankola, Ashraf Resheidat, Ziyad Binsalamah, Jun Teruya, Fabio Savorgnan, David F Vener
OBJECTIVES: To compare the incidences of postoperative thrombotic complications, transfusion of blood products, and chest tube output in congenital cardiac surgical patients who received either recombinant activated factor VII (rFVIIa) or 4-factor prothrombin complex concentrate (4F-PCC). DESIGN: We performed a retrospective study. SETTING: Patients who underwent surgery at a tertiary academic hospital. PARTICIPANTS: Pediatric patients who underwent cardiac surgery...
November 30, 2023: Journal of Cardiothoracic and Vascular Anesthesia
https://read.qxmd.com/read/38103737/a-multi-trait-genetic-study-of-hemostatic-factors-and-hemorrhagic-transformation-after-stroke-treatment
#19
JOURNAL ARTICLE
Cristina Gallego-Fabrega, Gerard Temprano-Sagrera, Jara Cárcel-Márquez, Elena Muiño, Natalia Cullell, Miquel Lledós, Laia Llucià-Carol, Jesús M Martin-Campos, Tomás Sobrino, José Castillo, Mònica Millán, Lucía Muñoz-Narbona, Elena López-Cancio, Marc Ribó, Jose Alvarez-Sabin, Jordi Jiménez-Conde, Jaume Roquer, Silvia Tur, Victor Obach, Juan F Arenillas, Tomas Segura, Gemma Serrano-Heras, Joan Marti-Fabregas, Marimar Freijo-Guerrero, Francisco Moniche, Maria Del Mar Castellanos, Alanna C Morrison, Nicholas L Smith, Paul S de Vries, Israel Fernandez-Cadenas, Maria Sabater-Lleal
BACKGROUND: Thrombolytic recombinant tissue-plasminogen activator (r-tPA) treatment is the only pharmacological intervention available in the ischemic stroke acute phase. This treatment is associated with an increased risk of intracerebral hemorrhages, known as hemorrhagic transformations (HT), which worsen patient's prognosis. OBJECTIVES: To investigate the association between genetically-determined natural hemostatic factors' levels, with increased risk of HT after r-tPA treatment...
December 14, 2023: Journal of Thrombosis and Haemostasis: JTH
https://read.qxmd.com/read/38036397/recombinant-activated-factor-vii-rfviia-for-bleeding-after-thoracic-aortic-surgery-a-scoping-review-of-current-literature
#20
REVIEW
Ryan Navarro, Sandra Bojic, Rubab Fatima, Mohamed El-Tahan, Mohammad El-Diasty
BACKGROUND: Bleeding after surgery on the thoracic aorta is a frequent complication, and can be associated with a significant increase in morbidity and mortality. Recombinant activated factor VII (rFVIIa) was developed initially for treating patients with hemophilia; however, it has been used increasingly "off-label" to achieve hemostasis after thoracic aortic procedures. OBJECTIVE: This scoping review aimed to present the available literature on the role of rFVIIa in the management of refractory postoperative bleeding after thoracic aortic surgery...
October 27, 2023: Journal of Cardiothoracic and Vascular Anesthesia
keyword
keyword
57377
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.